SaveHealth reports on cholesterol medications, detailing common types like statins, their effects, and safety considerations ...

Eligible patients with high cholesterol (LDL-C ≥70 mg/dL or non-high-density lipoprotein cholesterol [non-HDL-C] ≥100 mg/dL) and clinically evident ASCVD at more than 1,300 study locations around the ...

(HealthDay News) — Repatha (evolocumab) has been approved by the U.S. Food and Drug Administration, the second non-statin drug in its class approved to treat high cholesterol. The injected drug, among ...

THOUSAND OAKS, Calif., Aug. 25, 2025 /PRNewswire/ -- Amgen (AMGN) today announced that the U.S. Food and Drug Administration (FDA) has broadened the approved use of Repatha ® (evolocumab) to include ...

Heart attacks are often the result of vulnerable plaque ruptures. 1,2,3,4,5 Key features of vulnerable plaques are a large lipid core with a thin fibrous cap that serves as a wall or barrier around ...

Amgen’s Repatha was heralded recently in the media, generating headlines like "New Drug Prevents Heart Attacks in High-Risk Patients." But the company's stock then fell. Who should we believe and why?

WASHINGTON (Reuters) - The U.S. Food and Drug Administration on Thursday approved Amgen Inc's Repatha drug for patients with hereditary forms of high cholesterol and those with cardiovascular disease.

The FINANCIAL — On July 21 Amgen announced that the European Commission (EC) has granted marketing authorization for Repatha (evolocumab), the first proprotein convertase subtilisin/kexin type 9 ...

The FINANCIAL — THOUSAND OAKS, Calif. — Amgen announced the upcoming presentation of new Repatha (evolocumab) analyses, including a late-breaking study evaluating the efficacy of Repatha in patients ...

TRENTON, N.J. (AP) — The maker of an expensive cholesterol drug is slashing the list price, which should make it more affordable for patients. Amgen Inc. said Wednesday it is immediately cutting the ...